# 2025-08151: Blood Clot Testing Device for Surgery Now Class II Approved

2025-08151, Medical Devices; Hematology and Pathology Devices; Classification of the Coagulation System for the Measurement of Whole Blood Viscoelastic Properties in Perioperative Patients, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08151
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08151
- Title: Medical Devices; Hematology and Pathology Devices; Classification of the Coagulation System for the Measurement of Whole Blood Viscoelastic Properties in Perioperative Patients
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19629
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

Blood Clot Testing Device for Surgery Now Class II Approved

## Summary

The FDA is officially classifying a special blood test device used during surgery as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on May 9, 2025, and could save time and money for makers and users of these devices.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is classifying the coagulation system for the measurement of whole blood viscoelastic properties in perioperative patients into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the coagulation system for the measurement of whole blood viscoelastic properties in perioperative patients' classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Device moved to Class II (special controls): benefit, medium. The FDA officially classified the coagulation system for measuring whole blood viscoelastic properties in perioperative patients as Class II (special controls). This classification is effective May 9, 2025 and was applicable March 12, 2019. FDA says this reduces regulatory burdens and will enhance…
- De Novo gives a predicate for future devices: benefit, medium. Because FDA classified this device through the De Novo process, it can serve as a predicate for future devices of the same type, allowing other sponsors to use the less-burdensome 510(k) process instead of De Novo or premarket approval. FDA says this change can reduce regulatory burdens and save ti…
- Labeling limits on diagnostic claims: benefit, low. The device's labeling must say the device results are not intended to be the sole basis for a patient diagnosis. Unless specific clinical outcome studies are done and acceptable to FDA, labeling must also state the device has not been evaluated to guide blood product use or to guide medication use.
- Detailed study and testing requirements for manufacturers: cost, high. Manufacturers must provide detailed design verification and validation, including precision studies, performance across the claimed measurement range, interferent testing, specimen stability, and multisite clinical studies. The rule requires multisite clinical testing at a minimum of three external…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08151 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08151/medical-devices-hematology-and-pathology-devices-classification-of-the-coagulation-system-for-the)
- [2025-08151 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08151.pdf)

## Related
- [Previous: 2025-08150, Medical Devices; Immunology and Microbiology Devices; Classification of the Dev…](https://policyrisk.com/federal-register/2025-08150)
- [Next: 2025-08169, Safety Zone; Fireworks Displays Within the Fifth Coast Guard District; The Whar…](https://policyrisk.com/federal-register/2025-08169)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08151 (as of 2026-10-16).
